{"title":"Chest pain in adolescents: distinguishing cardiac from noncardiac causes","authors":"MD Monica Martin Goble","doi":"10.1016/S1082-7579(96)00087-8","DOIUrl":"10.1016/S1082-7579(96)00087-8","url":null,"abstract":"<div><p>Chest pain, a common problem motivating adults to seek medical care, occurs frequently in adolescents. Physicians may embark on a sequence of nonproductive investigations that can be costly and anxietyprovoking for the adolescent and parent. This review attempts to simplify the medical evaluation and management of the young patient with chest pain. Idiopathic chest pain is the most common diagnosis for childhood and adolescent chest pain, accounting for about 40% of cases. Of those cases for which a cause is found, musculoskeletal causes are most common, accounting for at least 20% of chest pain. Hyperventilation or panic disorders account for 10 to 20% of diagnoses. Noncardiac chest pain typically occurs at rest, which is helpful in distinguishing it from cardiac pain. In those with exercise-induced chest pain asthma must be carefully sought. Congenital coronary artery anomalies leading to angina must also be considered in those with exertional chest pain. Although exertional chest pain should raise a red flag, not all exertional chest pain is worrisome; it may simply reflect poor conditioning or an anxious athlete. In these cases a normal cardiac evaluation including a normal treadmill exercise test with or without reproducible chest pain may help provide the reassurance the anxious athlete needs. After eliminating the possibility of a medical illness, the psychiatrist is in a unique position to provide reassurance and counseling because knowledge about recent life events and the adolescent's beliefs about the symptoms may be necessary prerequisites for successful treatment.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"2 1","pages":"Pages 28-31"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)00087-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78358263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Medical clearance and the psychiatric patient: An emergency medicine perspective","authors":"MS Steve Olivar, MD, FACP, FAEP John Timmons","doi":"10.1016/S1082-7579(96)00089-1","DOIUrl":"10.1016/S1082-7579(96)00089-1","url":null,"abstract":"<div><p>The psychiatrist and the emergency physician interact frequently in the course of the treatment and disposition of psychiatric patients in the Emergency Department setting. Adequate and meaningful communication between the specialties involved in the care of these patients is paramount. Costly and unnecessary medical workups can be avoided if a reasonable medical history and physical exam is performed by the psychiatrist, the emergency physician, or both, as appropriate. On the other hand, when suspicion exists on the part of the physician, focused laboratory and x-ray evaluations is both appropriate and necessary for the proper care of these patients. Complete history and physical exams, repeated periodically as necessary, and good communication are the keys to quality medical care for psychiatric patients.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"2 1","pages":"Pages 2-4"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)00089-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76157033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Treatment options for smoking cessation","authors":"PharmD Thea Moore","doi":"10.1016/S1082-7579(96)00090-8","DOIUrl":"10.1016/S1082-7579(96)00090-8","url":null,"abstract":"<div><p>Tobacco use is considered the number one avoidable cause of morbidity and mortality in the United States. Considering the impact of tobacco use on the public health and economy, smoking cessation is an important concern for society as a whole. Higher prevalence of cigarette smoking among patients with psychiatric disorders makes smoking cessation an especially important issue for psychiatrists. Nicotine replacement therapy is the only FDA approved treatment for smoking cessation. Nicotine replacement is available in the form of gum, transdermal systems, and nasal spray. With the knowledge of available nonpharmacologic and pharmacologic treatments, and with recognition of the potential effects of smoking cessation on diagnosis and treatment of psychiatric disorders, psychiatrists can appropriately manage patients who are attempting to abstain from cigarette smoking.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"2 1","pages":"Pages 11-16"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)00090-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90963039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prenatal care of the low-risk patient","authors":"MD Ashlesha K. Dayal, MD, FACOG Jordan Pritzker","doi":"10.1016/S1082-7579(96)00116-1","DOIUrl":"10.1016/S1082-7579(96)00116-1","url":null,"abstract":"","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"2 1","pages":"Pages 24-27"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)00116-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86926788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rational pharmacotherapy for Alzheimer's disease","authors":"MD Martin Steinberg, MD, MHS Constantine Lyketsos","doi":"10.1016/S1082-7579(96)00111-2","DOIUrl":"10.1016/S1082-7579(96)00111-2","url":null,"abstract":"<div><p>Alzheimer's disease is commonly encountered by physicians in all specialties. The anticholinesterase inhibitors tacrine and donepezil are FDA-approved to treat the disease, and many more agents are being studied. Such agents may reverse the underlying disease process, salvage injured neurons, prevent amplification of neuronal death, or replace neurotransmitter loss after cell death occurs. This article presents a rational framework for understanding at which step in the neurodegenerative sequence various agents act. A discussion of the noncognitive symptoms of Alzheimer's disease and available treatment options for these ensues, followed by the presentation of a framework for providing comprehensive care consisting of treatment of the disease and its symptoms, as well support for the patient and family/caregiver.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"2 1","pages":"Pages 5-10"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)00111-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74931432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Psychiatric implications of medications used in human immunodeficiency virus disease","authors":"PharmD Michelle A. Gravlin","doi":"10.1016/S1082-7579(96)00115-X","DOIUrl":"10.1016/S1082-7579(96)00115-X","url":null,"abstract":"<div><p>Between four and seven percent of patients admitted to psychiatric hospitals are infected with Human Immunodeficiency Virus (HIV). Psychiatric patients are at a higher risk for developing HIV because they are more likely to engage in high-risk sexual behaviors, have higher rates of substance abuse than other populations, and are less knowledgeable about AIDS. HIV positive patients are at increased risk for adverse drug reactions; therefore, psychiatrists need to be aware of potential neurologic and psychiatric adverse effects of medications commonly used for HIV. For example, many of the common adverse effects associated with agents used in the treatment of HIV mimic signs and symptoms of depression. Also, antiretroviral therapy is rapidly changing and several new agents have become available. It is imperative for psychiatrists to be aware of drug interactions between psychotropic agents and antiretrovirals, particularly the protease inhibitors. The potential for drug interactions is significant because more than half of the psychotropic agents available today as well as five of the eleven HIV agents described in this article are metabolized by or affect drug metabolism through the Cytochrome P450 system. Collaboration with the patients' other prescribers or pharmacists and knowledge of all concurrent medications the patients are taking are the key to preventing adverse events because of drug interactions.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"2 1","pages":"Pages 17-23"},"PeriodicalIF":0.0,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)00115-X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75596491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Author index for volume 1","authors":"","doi":"10.1016/S1082-7579(96)80053-7","DOIUrl":"https://doi.org/10.1016/S1082-7579(96)80053-7","url":null,"abstract":"","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"1 6","pages":"Page 206"},"PeriodicalIF":0.0,"publicationDate":"1996-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)80053-7","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92019211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Childhood asthma","authors":"MD Susan Burke , MSN, PNP Kathy King","doi":"10.1016/S1082-7579(96)80051-3","DOIUrl":"https://doi.org/10.1016/S1082-7579(96)80051-3","url":null,"abstract":"<div><p>Asthma is the most common chronic childhood disease. A variety of factors trigger exacerbations including irritants, allergens, cold air, and exercise. The presence of wheezing can not be relied upon as a diagnostic criteria, as signs and symptoms of the disease such as cough and tachypnea may be very subtle. Treatment focuses on efforts to control bronchospasm, inflammation, and exposure to environmental triggers. Pharmacologic agents used are /32 agonists, theophylline, corticosteroids, and cromolyn sodium. Management varies depending on the severity of the disease and follows the National Asthma Education Program Guideline. Asthma education of practitioners, families, and patients is an integral component of successful management of this significant childhood illness.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"1 6","pages":"Pages 197-200"},"PeriodicalIF":0.0,"publicationDate":"1996-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)80051-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92079600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Detection and management of dyslipidemias in the psychiatric patient population","authors":"PharmD Maqual R. Infranca","doi":"10.1016/S1082-7579(96)80052-5","DOIUrl":"10.1016/S1082-7579(96)80052-5","url":null,"abstract":"<div><p>Coronary heart disease (CHD) accounts annually for half of all deaths in the United States. The morbidity and mortaility of CHD can be reduced with early and aggressive treatment. Mentally illnesses are at special risk because of their associated higher rates of smoking compared with the general population. Risk factor modification is a necessary component of the treatment plan and includes smoking cessation, weight reduction, increased physical activity, or a combination of these. Using guidelines set forth by the National Cholesterol Education Program, psychiatric physicians can screen for patients with elevated cholesterol, provide education or methods to modify risk factors, initiate cholesterol-lowering therapy, and monitor patients to ensure that goal low-density lipoprotein is achieved. The clinical outcome anticipated is reduced risk of cardiovascular-related event and decreased cost to the health care system.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"1 6","pages":"Pages 201-205"},"PeriodicalIF":0.0,"publicationDate":"1996-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)80052-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72915557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
MD, MPH Lori A. Bastian , PhD M. Christine Crenshaw , MD David C. Steffens
{"title":"Insomnia: A Practical Review","authors":"MD, MPH Lori A. Bastian , PhD M. Christine Crenshaw , MD David C. Steffens","doi":"10.1016/S1082-7579(96)80048-3","DOIUrl":"10.1016/S1082-7579(96)80048-3","url":null,"abstract":"<div><p>Insomnia has two components: the subjective complaint of trouble sleeping and a perceived daytime consequence of the nocturnal problem. The prevalence of insomnia in the general population is high, and the problem increases with increasing age. Psychiatrists usually encounter insomnia complaints that result from either comorbid mental illness or a side effect of pharmacotherapy. Clinicians should be aware of the multiple non-psychiatric causes of insomnia and be familiar with common primary sleep disorders. Obtaining a medical and sleep history is a critical first step in securing a diagnosis. Polysomnographic measurements, although not always necessary, provide definitive information that will assist in diagnosing sleep disorders. When the diagnosis requires monitoring the patient in a sleep laboratory, the clinician may choose to consult a sleep specialist. In general, drug therapy is recommended only as an adjunctive measure and on a short-term basis. Treatment should be directed at the underlying condition, management of stress, and improvement of sleep hygiene. This review, with case examples, highlights some common etiologies of insomnia, outlines both pharmaeologic and nonpharmacologic treatment options, and discusses when to refer potential sleep disorder cases to a specialist.</p></div>","PeriodicalId":100909,"journal":{"name":"Medical Update for Psychiatrists","volume":"1 6","pages":"Pages 183-187"},"PeriodicalIF":0.0,"publicationDate":"1996-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1082-7579(96)80048-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74399490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}